Compare Medtronic PLC (MDT) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs PubMatic Inc — how do they compare? Medtronic PLC trades at $87.57 (market cap $109.38B), while PubMatic Inc trades at $18.56 (market cap $845.86M). The key difference: Medtronic PLC is far larger — about 129.3× PubMatic Inc's market cap, and Medtronic PLC pays a 3.37% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and PubMatic Inc for 40 Days on average.
| MDT | PUBM | |
|---|---|---|
Market Cap | $109.38B | $845.86M |
Volume | 55,890,185 | 519,667 |
Sector | Health | Technology |
52-Week High | $105.35 | $19.18 |
52-Week Low | $73.75 | $6.28 |
Typical Hold Time | 63 Days | 40 Days |
Enterprise Value | $128.71B | $748.99M |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
PubMatic (PUBM) trades at $18.68, up 1.8% with bullish technical signals and strong analyst support. The stock shows positive momentum with recent earnings beats and double-digit revenue growth in Q2 2026. Despite negative net margins, the company maintains robust gross margins of 64.43% and positive operating cash flow of $81.06M in 2025. Recent leadership appointments and AI product launches signal strategic growth initiatives.
The outlook remains cautiously optimistic with Wall Street consensus at Buy (64.7%) and $19.89 price target. Key risks include persistent profitability challenges and competitive pressures in digital advertising. The stock's elevated P/E of 132 reflects growth expectations but requires sustained execution to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
